重组佐剂抗带状疱疹疫苗(RZV)在高危人群中的安全性:意大利普利亚大区2021-2023年主动监测数据
本研究为回顾性人群研究,纳入2021年10月1日至2023年3月31日在巴里综合医院接种门诊接种RZV的高危患者538例,共接种1031剂。结果显示每100剂随访中报告42.7例不良事件,严重不良事件0.38/100;12例(2.23%)报告基础疾病 flare-up,12例(2.43%)在长期随访中发生至少一次带状疱疹。作者认为RZV在高危人群中安全性良好,应主动推荐作为定制疫苗接种规划的一部分。
要点
- 538例高危患者共接种1031剂RZV,每100剂随访报告42.7例不良事件,严重不良事件0.38/100。
- 12例(2.23%)在接种后3个月内报告基础慢性病 flare-up,风湿病患者复发风险OR 16.56(95CI 3.58-76.56)。
- 12例完成接种周期者(2.43%)在长期随访中发生至少一次带状疱疹。
核心结论
- 研究显示RZV在大量高危患者中安全性良好,作者认为应主动将RZV作为定制疫苗接种规划的一部分提供,以降低脆弱人群的带状疱疹负担。
研究设计与样本
- 回顾性人群研究,纳入2021年10月1日至2023年3月31日在巴里综合医院接种门诊接种RZV的患者,共538例、1031剂。
- 筛查受试者RZV接种资格原因和基线慢性病,收集接种后7天内不良事件,并通过3个月随访评估基础疾病 flare-up 和接种后带状疱疹发作。
主要发现
- 538例患者中大多数因正在接受免疫抑制治疗而接种(54.65%),肿瘤血液病和心血管疾病是最常见的慢性基线疾病。
- 1031次随访中报告441例不良事件(42.7/100),最常见为注射部位疼痛/瘙痒(35.60/100)、乏力/不适(11.44/100)和发热(10.09/100)。
- 发生4例严重不良事件(0.38/100)。
- 高龄、男性和心血管疾病史(OR 0.71;95CI 0.52-0.98;p值<0.05)降低不良事件风险,内分泌代谢疾病(OR 1.61;95CI 1.15-2.26;p值<0.05)增加风险。
- 12例患者(2.23%)在接种后前3个月内报告基础慢性病 flare-up/加重(平均间隔31.75天,范围0-68天);风湿病患者复发风险更高(OR 16.56;95CI 3.58-76.56;p值<0.001),男性为保护因素。
临床怎么用
- 作者认为RZV在高危患者中安全性良好,应主动作为定制疫苗接种规划的一部分提供,以降低脆弱人群的带状疱疹负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since 2021 a recombinant adjuvanted anti-Herpes Zoster vaccine(Recombinant Zoster Vaccine, RZV) is offered in Italy to high-risk patients. Few real-life data about RZV safety are available in target populations. OBJECTIVES: This study investigates Adverse Events Following Immunization(AEFIs), baseline disease flare-ups, and Herpes Zoster (HZ) episodes occurring after RZV administration in a heterogeneous population of fragile patients to design its safety profile. METHODS: This is a retrospective population-based study. RZV-vaccinated patients at Bari Policlinico General Hospital vaccination clinic from October 1st, 2021, to March 31st, 2023, were enrolled. Subjects were screened for reason of RZV eligibility and baseline chronic pathologies. AEFIs occurred in the first 7-days post-vaccination period were collected, and baseline disease flare-ups and post-vaccination HZ episodes were assessed via a 3-month follow-up. RESULTS: Five-hundred-thirty-eight patients were included and total of 1,031 doses were administered. Most patients were vaccinated due to ongoing immunosuppressive therapy(54.65 %); onco-hematological and cardiovascular conditions were the most common chronic baseline pathologies. Out of 1,031 follow-ups, 441 AEFI cases were reported(42.7/100). The most common symptoms were injection site pain/itching(35.60/100), asthenia/malaise(11.44/100), and fever (10.09/100). Four serious AEFIs occurred(0.38/100). Older age, male sex, and history of cardiovascular diseases(OR:0.71; 95CI:0.52-0.98; p-value <0.05) were found to decrease AEFIs risk, while endocrine-metabolic illnesses(OR:1.61; 95CI:1.15-2.26; p-value <0.05) increased it. Twelve patients(2.23 %) reported a flare-up/worsening of their baseline chronic condition within the first three months after vaccination(mean interval 31.75 days, range 0-68 days). Patients with rheumatological illnesses had a higher risk of relapse(OR:16.56; 95CI:3.58-76.56; p-value <0.001), while male sex behaved as a protective factor. Twelve patients who completed the vaccination cycle(2.43%) had at least one HZ episode by the long-term follow-up. CONCLUSIONS: The study demonstrates RZV safety in a significant number of high-risk patients. Hence, RZV should be actively offered as part of tailored vaccination programs to decrease the burden of HZ in fragile populations.
引用
- Stefanizzi P, Moscara L, Palmieri C, et al. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23. Vaccine. 2024. PMID: 38582693. doi:10.1016/j.vaccine.2024.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。